News
-
-
PRESS RELEASE
Gerresheimer in H1 2025: Bormioli Pharma boosts revenues and earnings, continued market influences in operating business
Gerresheimer sees revenue growth in H1 2025, driven by Bormioli Pharma acquisition. Subdued demand in cosmetics and oral liquids market. Positive long-term outlook despite challenges -
-
-
-
-
-
PRESS RELEASE
Gerresheimer AG: Annual General Meeting approves key proposed resolutions by a large majority
Gerresheimer AG's Annual General Meeting approves key proposals with high approval rates including a dividend of EUR 0.04 per share for 2024. CEO Siemssen highlights progress on strategic topics and transformation into a solutions provider -
-